186 related articles for article (PubMed ID: 30403365)
21. Alemtuzumab and prescription medication use in the MS population.
Chertcoff A; Ng HS; Zhu F; Zhao Y; Kingwell E; Tremlett H
Mult Scler Relat Disord; 2020 Jul; 42():102086. PubMed ID: 32403069
[TBL] [Abstract][Full Text] [Related]
22. A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.
Ali L; Saxena G; Jones M; Leisegang GR; Gammon L; Gnanapavan S; Giovannoni G; Schmierer K; Baker D; Kang AS
Biotechniques; 2020 Apr; 68(4):185-190. PubMed ID: 32096651
[No Abstract] [Full Text] [Related]
23. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.
Li Z; Richards S; Surks HK; Jacobs A; Panzara MA
Clin Exp Immunol; 2018 Dec; 194(3):295-314. PubMed ID: 30144037
[TBL] [Abstract][Full Text] [Related]
24. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT
Mult Scler; 2017 May; 23(6):874-876. PubMed ID: 28290755
[TBL] [Abstract][Full Text] [Related]
25. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
Baker D; Herrod SS; Alvarez-Gonzalez C; Giovannoni G; Schmierer K
JAMA Neurol; 2017 Aug; 74(8):961-969. PubMed ID: 28604916
[TBL] [Abstract][Full Text] [Related]
26. Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis.
Kim Y; Kim G; Shin HJ; Hyun JW; Kim SH; Lee E; Kim HJ
J Neuroinflammation; 2018 Oct; 15(1):300. PubMed ID: 30373595
[TBL] [Abstract][Full Text] [Related]
27. Alemtuzumab in Covid era.
Iovino A; Olivieri N; Aruta F; Giaquinto E; Ruggiero L; Spina E; Tozza S; Manganelli F; Iodice R
Mult Scler Relat Disord; 2021 Jun; 51():102908. PubMed ID: 33812222
[TBL] [Abstract][Full Text] [Related]
28. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
[TBL] [Abstract][Full Text] [Related]
29. Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
Graf J; Ringelstein M; Lepka K; Schaller J; Quack H; Hartung HP; Aktas O; Albrecht P
Mult Scler; 2018 Nov; 24(13):1776-1778. PubMed ID: 30307371
[TBL] [Abstract][Full Text] [Related]
30. Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis.
McCaughan G; Massey J; Sutton I; Curnow J
BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29212866
[TBL] [Abstract][Full Text] [Related]
31. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
32. B cell treatments for multiple sclerosis.
McLauchlan D; Robertson NP
J Neurol; 2017 Apr; 264(4):814-816. PubMed ID: 28260119
[No Abstract] [Full Text] [Related]
33. [Magnetic resonance imaging in the course of alemtuzumab and teriflunomide therapy].
Mike A; Kincses ZT; Vécsei L
Ideggyogy Sz; 2017 Jan; 70(1-2):15-24. PubMed ID: 29870189
[TBL] [Abstract][Full Text] [Related]
34. Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
Midaglia L; Gratacòs M; Caronna E; Raguer N; Sastre-Garriga J; Montalban X; Tintoré M
Neurology; 2018 Sep; 91(13):622-624. PubMed ID: 30143565
[No Abstract] [Full Text] [Related]
35. B cell depletion therapy resulting in sustained remission of severe autoimmune complications following Alemtuzumab treatment of Multiple Sclerosis.
Massey J; Barnett Y; Curnow J; Sutton I
Mult Scler Relat Disord; 2019 Oct; 35():100-103. PubMed ID: 31357122
[TBL] [Abstract][Full Text] [Related]
36. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Arroyo González R; Kita M; Crayton H; Havrdova E; Margolin DH; Lake SL; Giovannoni G;
Mult Scler; 2017 Sep; 23(10):1367-1376. PubMed ID: 27885061
[TBL] [Abstract][Full Text] [Related]
37. Alemtuzumab depletion failure can occur in multiple sclerosis.
Dubuisson N; Baker D; Kang AS; Pryce G; Marta M; Visser LH; Hofmann WE; Gnanapavan S; Giovannoni G; Schmierer K
Immunology; 2018 Jun; 154(2):253-260. PubMed ID: 29247512
[TBL] [Abstract][Full Text] [Related]
38. Alemtuzumab: the advantages and challenges of a novel therapy in MS.
Menge T; Stüve O; Kieseier BC; Hartung HP
Neurology; 2014 Jul; 83(1):87-97. PubMed ID: 24920854
[TBL] [Abstract][Full Text] [Related]
39. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
40. Alemtuzumab-induced remission of multiple sclerosis-associated uveitis.
Willis MD; Pickersgill TP; Robertson NP; Lee RWJ; Dick AD; Carreño E
Int Ophthalmol; 2017 Oct; 37(5):1229-1233. PubMed ID: 27730316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
